Tracer library / [90Y]Y-FAPI

[90Y]Y-FAPI

Also written as [90Y]FAPI; [Y-90]FAPI; FAPI

Radionuclide: Y-90 t½ 3843 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

FAP-directed radioligand therapy

What it is

Compound class: FAP inhibitor (FAPI) radiotracer
Target / mechanism: Fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts (CAFs) PMID 41599688
Clinical application: Radionuclide therapy in oncology targeting tumour stroma/cancer-associated fibroblasts PMID 41599688
Theranostic pair: [68Ga]Ga-FAPI

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [90Y]Y-FAPI, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityOsmolalityMolar activityMetal impurities

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [90Y]Y-FAPI.

Get in touch

Notes

Added from reverse module search (stage 6); 4 article(s) with Y-90. Stage set/updated at stage 39 from PMID 41599688: 'Therapeutic evidence shows encouraging tumour retention and safety profiles for agents such as [177Lu]Lu-FAP-2286 and [90Y]Y-FAPI-46'.